Contributing factors to methadone-related deaths in Ontario

American Journal of Forensic Medicine and Pathology

Volumn 31, Issue 4, 2010, Pages 313-319

  Albion, Caroline ^a   Shkrum, Michael ^a   Cairns, James ^b  

^a WESTERN UNIVERSITY   (Canada)

^b Ministry of Community Safety and Correctional Services   (Canada)

Author keywords

Illicit drug abuse; methadone maintenance treatment; mortality; opioids

Indexed keywords

ALCOHOL; CANNABINOID; CENTRAL DEPRESSANT AGENT; METHADONE; NARCOTIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD; CANADA; FEMALE; FORENSIC PATHOLOGY; FORENSIC TOXICOLOGY; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE; HUMAN; INTOXICATION; LIVER; LUNG; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGED; MORTALITY; PATHOLOGY; PNEUMONIA; RETROSPECTIVE STUDY; SEPSIS; SEX RATIO; SUICIDE; TRAFFIC ACCIDENT; URINE;

ACCIDENTS, TRAFFIC; ADULT; AGE DISTRIBUTION; CANNABINOIDS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; ETHANOL; FEMALE; FORENSIC PATHOLOGY; FORENSIC TOXICOLOGY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER; LUNG; MALE; METHADONE; MIDDLE AGED; MYOCARDIUM; NARCOTICS; ONTARIO; OVERDOSE; PNEUMONIA; RETROSPECTIVE STUDIES; SEPSIS; SEX DISTRIBUTION; SUICIDE;

EID: 78650447465     PISSN: 01957910     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAF.0b013e3181ca4b1e     Document Type: Article

References (35)

1. Fischer B, Rehm J, Brisette S, et al. Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health. 2005;82: 250-266.
2. Brown R, Kraus C, Fleming M, et al. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J. 2004;80:654-659.
3. Rang HP, Dale MM, Ritter JM, et al. Pharmacology. 5th ed. Philadelphia, PA: Churchhill Livingstone; 2003.
4. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18:S3-S13.
5. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94:961-972.
6. Corkery JM, Schifano F, Ghodse AH, et al. The effects of methadone and its role in fatalities. Hum Psychopharmacol. 2004;19:565-576.
7. Ballesteros MF, Budnitz DS, Sanford CP, et al. Increase in deaths due to methadone in North Carolina. JAMA. 2003;290:40.
8. Information for healthcare professionalsYYmethadone hydrochloride. Available at: http://www.fda.gov/cder/drug/Infosheets/HCP/ methadoneHCP.htm. Accessed May 1, 2007.
9. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221-226.
10. Strike CJ, Urbanoski K, Fischer B, et al. Policy changes and the methadone maintenance treatment system for opioid dependence in Ontario, 1996 to 2001. J Addict Dis. 2005;24:39-51.
11. Sibbald B. Tighten Ontario's methadone program states inquest. CMAJ. 2005;172:319-320.
12. Inturrisi CE, Verebely K. The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther. 1972;13:633-637.
13. Clark JC, Milroy CM, Forrest AR. Deaths from methadone use. J Clin Forensic Med. 1995;2:143-144.
14. Kitzman DW, Scholz DG, Hagen PT, et al. Age-related changes in normal human hearts during the first 10 decades of life. Part II (Maturity): a quantitative anatomic study of 765 specimens from subjects 20 to 99 years old. Mayo Clin Proc. 1988;63:137-146.
15. Statistics Canada. CANSIM, table 5-0034 and Catalogue nos. 91-213-XIB and 91-213-XPB. Available at: http://www40.statcan. ca.proxy2.lib.uwo.ca:2048/l01/ cst01/demo05a.htm. Accessed April 1, 2006.
16. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000; 67:347-364.
17. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust. 1999;170:104-109.
18. Perret G, Deglon JJ, Kreek MJ, et al. Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction. 2000;95: 1647-1653.
19. Milroy CM, Forrest AR. Methadone deaths: a toxicological analysis. J Clin Pathol. 2000;53:277-281.
20. Worm K, Steentoft A, Kringsholm B. Methadone and drug addicts. Ugeskr Laeger. 1993;155:2245-2247.
21. Drummer OH, Opeskin Syrjanen M, et al. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. Am J Forensic Med Pathol. 1992;13:346-350.
22. Caplehorn JR, Drummer OH. Methadone dose and post-mortem blood concentration. Drug Alcohol Rev. 2002;21:329-333.
23. Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002;26:358-362; discussion 362-363.
24. Wolf BC, Lavezzi WA, Sullivan LM, et al. Alprazolam-related deaths in Palm Beach County. Am J Forensic Med Pathol. 2005;26:24-27.
25. Karch SB, Stephens BG. Toxicology and pathology of deaths related to methadone: retrospective review. West J Med. 2000;172:11-14.
26. Ferrari A, Coccia CP, Bertolini A, et al. MethadoneYmetabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50:551-559.
27. Begre S, von Bardeleben U, Ladewig D, et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol. 2002;22:211-215.
28. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003;31:742-747.
29. Appel PW, Joseph H, Richman BL. Causes and rates of death among methadone maintenance patients before and after the onset of the HIV/AIDS epidemic. Mt Sinai J Med. 2000;67:444-451.
30. Wilson KC, Saukkonen JJ. Acute respiratory failure from abused substances. J Intensive Care Med. 2004;19:183-193.
31. Ashwath ML, Ajjan M, Culclasure T. Methadone-induced bradycardia. J Emerg Med. 2005;29:73-75.
32. Sticherling C, Schaer BA, Ammann P, et al. Methadone-induced Torsade de pointes tachycardias. Swiss Med Wkly. 2005;135:282-285.
33. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137: 501-504.
34. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet. 1995;29:370-391.
35. Novick DM, Kreek MJ, Fanizza AM, et al. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981;30:353-362.